Medivir AB (LTS:0GP7) Interest Expense : kr-2.49 Mil (TTM As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Medivir AB Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Medivir AB's interest expense for the three months ended in Mar. 2024 was kr 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was kr-2.49 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Medivir AB's Operating Income for the three months ended in Mar. 2024 was kr -27.40 Mil. Medivir AB's Interest Expense for the three months ended in Mar. 2024 was kr 0.00 Mil. Medivir AB has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Medivir AB Interest Expense Historical Data

The historical data trend for Medivir AB's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medivir AB Interest Expense Chart

Medivir AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-1.32

-0.55

-0.95

-0.93

-0.91

Medivir AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-	-	-	-2.49	-

Medivir AB Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-2.49 Mil.

Medivir AB (LTS:0GP7) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Medivir AB's Interest Expense for the three months ended in Mar. 2024 was kr0.00 Mil. Its Operating Income for the three months ended in Mar. 2024 was kr-27.40 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was kr0.00 Mil.

Medivir AB's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Medivir AB had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Medivir AB (LTS:0GP7) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medivir AB (LTS:0GP7) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

MVIR:Sweden MVR0:Germany MVR0:Germany

Address

Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22

Website

https://www.medivir.com

Medivir AB develops drugs with a focus on cancers where there are medical needs. The company invests in indication areas where available treatment methods are limited or lacking and there are opportunities to offer significant improvements to patients. Medivir focuses on the development of MIV-818, a prodrug that has been designed to provide a targeted anti-tumor effect in the liver while minimizing any side effects. Birinapant, a SMAC mimetic, has been out-licensed for development in combination with IGM antibodies for the treatment of solid tumors.

Medivir AB (LTS:0GP7) Headlines

No Headlines